A case of locally, advanced pancreatic cancer with superior membrane artery invasion successfully resected after gemcitabine-based chemoradiotherapy

Yoshiaki Ohmura, Yutaka Takeda, Hiroaki Nagano, Shoji Nakamori, Shogo Kobayashi, Shigeru Marubashi, Hidetoshi Eguchi, Masahiro Tanemura, Toru Kitagawa, Morito Monden, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 69-year-old man with chief complaint of epigastralgia was diagnosed as locally advanced borderline unresectable pancreatic head cancer that involved superior membrane artery (SMA); Gemcitabine (GEM) -based chemoradiotherapy (CRT) was administered for consecutive 3 weeks in the following fashion: continuous twice-a-day accelerated radiotherapy (2 daily fractions of 1.5 Gy, 5 days a week, with a 6-hr minimal interval between fractions) with 3-time weekly intravenous infusions of GEM. Total radiation dose was 45 Gy and GEM was given on days 1, 8 and 15 at dose of 800mg/m2. After the completion of CRT, the involvement of SMA remained. Next, additional systemic chemotherapy with GEM was performed for 3 weeks in the following fashion: weekly intravenous infusions of GEM at dose of 1, 000 mg/m2. Finally, the main tumor and the invasion to SMA were reduced. Surgical resection with negative margins (R0 resection) was performed. Adjuvant chemotherapy with 6 courses of GEM was also performed. The patient has no recurrence, suggesting the efficacy of GEM-based, CRT for locally advanced borderline unresectable pancreatic cancer.

Original languageEnglish
Pages (from-to)2428-2429
Number of pages2
JournalJapanese Journal of Cancer and Chemotherapy
Volume36
Issue number12
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

gemcitabine
Chemoradiotherapy
Pancreatic Neoplasms
Arteries
Membranes
Intravenous Infusions
Adjuvant Chemotherapy
Head and Neck Neoplasms
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

A case of locally, advanced pancreatic cancer with superior membrane artery invasion successfully resected after gemcitabine-based chemoradiotherapy. / Ohmura, Yoshiaki; Takeda, Yutaka; Nagano, Hiroaki; Nakamori, Shoji; Kobayashi, Shogo; Marubashi, Shigeru; Eguchi, Hidetoshi; Tanemura, Masahiro; Kitagawa, Toru; Monden, Morito; Mori, Masaki; Doki, Yuichiro.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 36, No. 12, 2009, p. 2428-2429.

Research output: Contribution to journalArticle

Ohmura, Y, Takeda, Y, Nagano, H, Nakamori, S, Kobayashi, S, Marubashi, S, Eguchi, H, Tanemura, M, Kitagawa, T, Monden, M, Mori, M & Doki, Y 2009, 'A case of locally, advanced pancreatic cancer with superior membrane artery invasion successfully resected after gemcitabine-based chemoradiotherapy', Japanese Journal of Cancer and Chemotherapy, vol. 36, no. 12, pp. 2428-2429.
Ohmura, Yoshiaki ; Takeda, Yutaka ; Nagano, Hiroaki ; Nakamori, Shoji ; Kobayashi, Shogo ; Marubashi, Shigeru ; Eguchi, Hidetoshi ; Tanemura, Masahiro ; Kitagawa, Toru ; Monden, Morito ; Mori, Masaki ; Doki, Yuichiro. / A case of locally, advanced pancreatic cancer with superior membrane artery invasion successfully resected after gemcitabine-based chemoradiotherapy. In: Japanese Journal of Cancer and Chemotherapy. 2009 ; Vol. 36, No. 12. pp. 2428-2429.
@article{bdafad4f86074e60bac30d38ede46b6f,
title = "A case of locally, advanced pancreatic cancer with superior membrane artery invasion successfully resected after gemcitabine-based chemoradiotherapy",
abstract = "A 69-year-old man with chief complaint of epigastralgia was diagnosed as locally advanced borderline unresectable pancreatic head cancer that involved superior membrane artery (SMA); Gemcitabine (GEM) -based chemoradiotherapy (CRT) was administered for consecutive 3 weeks in the following fashion: continuous twice-a-day accelerated radiotherapy (2 daily fractions of 1.5 Gy, 5 days a week, with a 6-hr minimal interval between fractions) with 3-time weekly intravenous infusions of GEM. Total radiation dose was 45 Gy and GEM was given on days 1, 8 and 15 at dose of 800mg/m2. After the completion of CRT, the involvement of SMA remained. Next, additional systemic chemotherapy with GEM was performed for 3 weeks in the following fashion: weekly intravenous infusions of GEM at dose of 1, 000 mg/m2. Finally, the main tumor and the invasion to SMA were reduced. Surgical resection with negative margins (R0 resection) was performed. Adjuvant chemotherapy with 6 courses of GEM was also performed. The patient has no recurrence, suggesting the efficacy of GEM-based, CRT for locally advanced borderline unresectable pancreatic cancer.",
author = "Yoshiaki Ohmura and Yutaka Takeda and Hiroaki Nagano and Shoji Nakamori and Shogo Kobayashi and Shigeru Marubashi and Hidetoshi Eguchi and Masahiro Tanemura and Toru Kitagawa and Morito Monden and Masaki Mori and Yuichiro Doki",
year = "2009",
language = "English",
volume = "36",
pages = "2428--2429",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - A case of locally, advanced pancreatic cancer with superior membrane artery invasion successfully resected after gemcitabine-based chemoradiotherapy

AU - Ohmura, Yoshiaki

AU - Takeda, Yutaka

AU - Nagano, Hiroaki

AU - Nakamori, Shoji

AU - Kobayashi, Shogo

AU - Marubashi, Shigeru

AU - Eguchi, Hidetoshi

AU - Tanemura, Masahiro

AU - Kitagawa, Toru

AU - Monden, Morito

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2009

Y1 - 2009

N2 - A 69-year-old man with chief complaint of epigastralgia was diagnosed as locally advanced borderline unresectable pancreatic head cancer that involved superior membrane artery (SMA); Gemcitabine (GEM) -based chemoradiotherapy (CRT) was administered for consecutive 3 weeks in the following fashion: continuous twice-a-day accelerated radiotherapy (2 daily fractions of 1.5 Gy, 5 days a week, with a 6-hr minimal interval between fractions) with 3-time weekly intravenous infusions of GEM. Total radiation dose was 45 Gy and GEM was given on days 1, 8 and 15 at dose of 800mg/m2. After the completion of CRT, the involvement of SMA remained. Next, additional systemic chemotherapy with GEM was performed for 3 weeks in the following fashion: weekly intravenous infusions of GEM at dose of 1, 000 mg/m2. Finally, the main tumor and the invasion to SMA were reduced. Surgical resection with negative margins (R0 resection) was performed. Adjuvant chemotherapy with 6 courses of GEM was also performed. The patient has no recurrence, suggesting the efficacy of GEM-based, CRT for locally advanced borderline unresectable pancreatic cancer.

AB - A 69-year-old man with chief complaint of epigastralgia was diagnosed as locally advanced borderline unresectable pancreatic head cancer that involved superior membrane artery (SMA); Gemcitabine (GEM) -based chemoradiotherapy (CRT) was administered for consecutive 3 weeks in the following fashion: continuous twice-a-day accelerated radiotherapy (2 daily fractions of 1.5 Gy, 5 days a week, with a 6-hr minimal interval between fractions) with 3-time weekly intravenous infusions of GEM. Total radiation dose was 45 Gy and GEM was given on days 1, 8 and 15 at dose of 800mg/m2. After the completion of CRT, the involvement of SMA remained. Next, additional systemic chemotherapy with GEM was performed for 3 weeks in the following fashion: weekly intravenous infusions of GEM at dose of 1, 000 mg/m2. Finally, the main tumor and the invasion to SMA were reduced. Surgical resection with negative margins (R0 resection) was performed. Adjuvant chemotherapy with 6 courses of GEM was also performed. The patient has no recurrence, suggesting the efficacy of GEM-based, CRT for locally advanced borderline unresectable pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84864579511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864579511&partnerID=8YFLogxK

M3 - Article

C2 - 20037445

AN - SCOPUS:84864579511

VL - 36

SP - 2428

EP - 2429

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -